ulcerative proctitis
Jump to navigation
Jump to search
Introduction
see Proctitis
Pathology
- rectal mucosa may show
- loss of vascular markings
- erythema
- friability
- chronic inflammation
- crypt distortion, crypt atrophy
Clinical manifestations
Complications
- little if any increased risk of colon cancer if inflammation is confined to rectum (contrast with ulcerative colitis)
Management
- colon cancer screening per schedule without risk factors
- mesalamine suppositories (Rowasa) 500 mg 1st line
- rectal glucocorticoid if intolerant of mesalamine
- effective for induction but not maintenance of remission
- hydrocortisone suppositories (Anusol-HC) 25 mg
- hydrocortisone foam (Cortifoam)
- budesonide MMX (Entocort EC, Uceris, Cortiment)
- sulfasalazine
- folate supplementation with sulfasalazine
- sulfasalazine inhibits folate absorption[3]
- folate supplementation with sulfasalazine
More general terms
Additional terms
References
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
- ↑ 2.0 2.1 Sandborn WJ et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology 2015 Jan 30 <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/25644096 <Internet> http://www.gastrojournal.org/article/S0016-5085%2815%2900154-7/abstract
- ↑ 3.0 3.1 NEJM Knowledge+ Gastroenterology